Julia Thornton Snider (Julia T Snider)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 8

Top Topics

Acute Lymphoblastic Leukemia

Top Venues

Journal of medical economics

Leukemia & lymphoma

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Diane Ito, Chaoling Feng, Christine Fu, Chong Kim, James Wu, Josh Epstein, Julia Thornton Snider, Adam S DuVall
Health resource utilization and costs of care for adult patients with relapsed or refractory mantle cell lymphoma in the United States: a retrospective claims analysis. Expert review of pharmacoeconomics & outcomes research (2023)
Jason R Westin, Frederick L Locke, Michael J Dickinson, Armin Ghobadi, Mahmoud Elsawy, Tom van Meerten, David Bernard Miklos, Matthew L Ulrickson, Miguel-Ángel Perales, Umar Farooq, Luciano Wannesson, Lori A Leslie, Marie José Kersten, Caron A Jacobson, John M Pagel, Gerald Georg Wulf, Patrick B Johnston, Aaron P Rapoport, Linqiu Du, Saran Vardhanabhuti, Simone Filosto, Jina Shah, Julia Thornton Snider, Paul Cheng, Christina To, Olalekan O Oluwole, Anna Sureda
Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Olalekan O Oluwole, Jenny M H Chen, Keith Chan, Anik R Patel, Jeroen P Jansen, Sam Keeping, Yan Zheng, Julia Thornton Snider, Frederick L Locke
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leukemia & lymphoma (2022)
Paola Ghione, M Lia Palomba, Anik R Patel, Sabela Bobillo, Kevin Deighton, Caron A Jacobson, Myrna Nahas, Anthony James Hatswell, A Scott Jung, Steve Kanters, Julia Thornton Snider, Sattva S Neelapu, Maria Teresa Ribeiro, M Alan Brookhart, Herve Ghesquieres, John Radford, John G Gribben
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood 140 (8) (2022)
Mahmoud Elsawy, Julio C Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D Rudzki, Saurabh Dahiya, Kathleen A Dorritie, Samantha M Jaglowski, John Radford, Judith Trotman, David Cunningham, Alejandro Martin Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood 140 (21) (2022)
Alice Kate Cummings Joyner, Julia Thornton Snider, Sally West Wade, Si-Tien Wang, Marric G Buessing, Scott J Johnson, Usama Gergis
Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care. Advances in therapy 39 (8) (2022)
Olalekan O Oluwole, Rongzhe Liu, Ibrahim Diakite, Chaoling Feng, Anik Patel, Iman Nourhussein, Julia Thornton Snider, Frederick L Locke
Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US. Journal of medical economics 25 (1) (2022)
Rongzhe Liu, Olalekan O Oluwole, Ibrahim Diakite, Marc F Botteman, Julia Thornton Snider, Frederick L Locke
Cost effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the United States. Journal of medical economics 24 (1) (2021)